We are live on ! Find out more

Eton Pharmaceutcials

ETON

Market cap $1.63B

57.08 USD

-0.80

1.38%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

57.10

+0.02

0.04%

1 day

-1.38%

5 days

-4.66%

1 month

35.74%

3 months

77.76%

6 months

215.53%

Year to date

251.05%

1 year

224.87%

5 years

1,025.84%

10 years

813.28%

About: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

Employees: 44

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 46.2%

Neutral 53.8%

Negative 0%

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Investors Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Three Biotech Stocks Stick Out With Their Stellar Charts

The Motley Fool

Why Eton Pharmaceuticals Is Top of the Class Today

Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.

Why Eton Pharmaceuticals Is Top of the Class Today

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Investors Business Daily

Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High

Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance.

Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

Eton Pharmaceuticals Q2 Earnings Call Highlights

Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.

Eton Pharmaceuticals Q2 Earnings Call Highlights

Zacks Investment Research

Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.

Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2026.

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

DEER PARK, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has licensed U.S. rights to rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals (“Auson”). ASN-001 is under development for the treatment of proliferating superficial infantile hemangiomas.

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

See News Rankings

Price charts implemented using Lightweight Charts™